Therapeutic Insights into Overcoming Therapy Resistance in BRAFV600E Melanoma
- Description
Although targeted cancer therapies have been successful, their efficacies are limited by the development of resistance driven by clonal evolution within tumors. This study developed a single-cell barcoding approach to comprehensively trace clonal dynamics and capture live lineage-coupled resistant cells for in-depth multi-omics analysis and functional exploration. They showed that heterogeneous clones, either preexisting or emerging from drug-tolerant persister cells, dominated resistance to vemurafenib in BRAFV600E melanoma. This dataset contains RNA sequencing, EPIC array, and whole-exome sequencing (WES) data.
The publication also includes supplementary data. The supplementary data contains several tables about editing outcomes of BC1 and BC2, guide RNA sequences for making the 36 million barcodes, barcode counts and GFOLDs of A375 treated with PLX, top barcodes for capture, summary of CNVs in the control and PLX-resistant subclones, and summary of gene expression (FPKM) in the control and PLX resistant subclones. It also contains tables about summary of SAs, summary of DMPs, summary of DMGs, summary of genes whose promoter methylation status correlated to RNA express change, p values of ratio test, and summary of primers used.
Access
- Restrictions
-
Free to All
- Instructions
- All RNA-seq and EPIC array data were deposited in the Gene Expression Omnibus (GEO) repository and all WES data were deposited to Sequence Read Archive (SRA).
- Grant Support
-
Defeat GBM Research Collaborative/National Brain Tumor Society